SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
Securities Exchange Act of 1934
For the month of August 2024
Commission File Number: 001-36349
MediWound Ltd.
(Translation of registrant’s name into English)
(Translation of registrant’s name into English)
42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7): ☐
EXPLANATORY NOTE
On August 15, 2024, MediWound Ltd. (the “Company”) issued a press release entitled “MediWound Announces U.S. Food
and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns”. A copy of this press release is attached to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) as Exhibit
99.1.
The content of this report on Form 6-K (including the information contained in Exhibit 99.1, but excluding quotes
of senior management of the Company), is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021
August 9, 2022 and August 15, 2023 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697 and 333-273997, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023
(Registration Nos. 333-265203 and 333-268297, respectively).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
| MEDIWOUND LTD. | |||
| Date: August 15, 2024 |
By:
|
/s/ Hani Luxenburg | |
| Name: | Hani Luxenburg | ||
| Title: |
Chief Financial Officer
|
||
3
EXHIBIT INDEX
The following exhibit is filed as part of this Form 6-K:
| Exhibit | Description |
| 99.1 |
4